According to the official answer, Kanghua Biological (stock code:300841) landed on the GEM board on June 16, 2020. Kanghua Biological public offering of 15 million shares, including 15 million new shares, the issue price of 7 million shares.37 yuan / share, new shares to raise funds of 10 yuan.56 billion yuan, after the issue of the total share capital of 60 million shares. Kanghua Biological is mainly engaged in the research and development, production and sales of vaccine products.In 2019, the company realized operating income of 555 million yuan, net profit of 186.6867 million yuan.
Weifang Kanghua Biotechnology Co., Ltd. was founded in 1996, is committed to the research and development and innovation of life and health and precision medical products, integrating the research and development, production and sales of external diagnostic reagents, testing and analyzing instruments and other products, and providing customers with the overall solution of medical diagnostic services. The main business covers clinical testing equipment, in vitro diagnostic reagents, medical electronics and other fields, enzyme immunoassay, POCT, chemiluminescence, biochemical detection, molecular detection of five platforms, more than 400 kinds of registered products, a long product line, fewer approval numbers, and a sales network throughout the world more than 120 countries and regions.
The company has a strict quality management system, to achieve the whole process of control from raw materials to the client; has an international advanced biological R & D laboratory, nearly 50,000 square meters GMP through the production workshop, mold processing workshop and technical team CFDA, ISO13485, EU CE a number of industry certifications; won the national contract and trustworthy enterprises, advanced taxpaying enterprises, Shandong China Patent Star Enterprise and many other honors. The company's trademark in April 2018 was recognized as a national well-known trademark.